Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most ...

In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...

An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

PURPOSE: To determine biologic differences, if any, between presurgical endocrine treatment with an aromatase inhibitor (vorozole) and tamoxifen in patients with postmenopausal primary breast cancer.

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...